Heterogeneity of prostate-specific membrane antigen (PSMA) expression in classic and apoptotic circulating tumor cells (CTC) in metastatic castration-resistant prostate cancer (mCRPC)

被引：1
|
作者：
Autio, Karen A.
Anand, Aseem
Krupa, Rachel
Louw, Jessica
Arslan, Zaina
Dittamore, Ryan
Scher, Howard I.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Epic Sci Inc, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.198
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
198
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane
    Petrylak, Daniel Peter
    Kantoff, Philip W.
    Mega, Anthony E.
    Vogelzang, Nicholas J.
    Stephenson, Joe
    Fleming, Mark T.
    Stambler, Nancy
    Petrini, Michaela
    Blattman, Sara
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel Peter
    Smith, David C.
    Appleman, Leonard Joseph
    Fleming, Mark T.
    Hussain, Arif
    Dreicer, Robert
    Sartor, A. Oliver
    Shore, Neal D.
    Vogelzang, Nicholas J.
    Youssoufian, Hagop
    DiPippo, Vincent A.
    Stambler, Nancy
    Huang, Kathleen
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane
    Petrylak, Daniel Peter
    Kantoff, Philip W.
    Mega, Anthony E.
    Vogelzang, Nicholas J.
    Stephenson, Joe
    Fleming, Mark T.
    Stambler, Nancy
    Petrini, Michaela
    Huang, Kathleen
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [24] Circulating tumor cells in metastatic castration-resistant prostate cancer
    Brian I. Rini
    Current Oncology Reports, 2009, 11 : 163 - 164
  • [25] A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel Peter
    Smith, David C.
    Appleman, Leonard Joseph
    Fleming, Mark T.
    Hussain, Arif
    Dreicer, Robert
    Sartor, A. Oliver
    Shore, Neal D.
    Vogelzang, Nicholas J.
    Youssoufian, Hagop
    Olson, William C.
    Stambler, Nancy
    Huang, Kathleen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [26] Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)
    Belli, Maria Luisa
    Sarnelli, Anna
    Mezzenga, Emilio
    Cesarini, Francesco
    Caroli, Paola
    Di Iorio, Valentina
    Strigari, Lidia
    Cremonesi, Marta
    Romeo, Antonino
    Nicolini, Silvia
    Matteucci, Federica
    Severi, Stefano
    Paganelli, Giovanni
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [27] Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer
    Weber, Manuel
    Hadaschik, Boris
    Ferdinandus, Justin
    Rahbar, Kambiz
    Beogemann, Martin
    Herrmann, Ken
    Fendler, Wolfgang P.
    Kesch, Claudia
    EUROPEAN UROLOGY FOCUS, 2021, 7 (02): : 279 - 287
  • [28] Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
    Mega, Anthony E.
    Petrylak, Daniel Peter
    Kantoff, Philip
    Stephenson, Joe
    Vogelzang, Nicholas J.
    Dreicer, Robert
    Shore, Neal D.
    Stambler, Nancy
    Carpenito, Jennifer
    D'Ambrosio, Paul
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Prostate-specific membrane antigen expression on positron emission tomography/computed tomography in patients with metastatic castration-resistant prostate cancer
    Calderoni, L.
    Maietti, E.
    Farolfi, A.
    Mei, R.
    Louie, K.
    Groaning, M.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S407 - S407
  • [30] Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
    Calderoni, Letizia
    Maietti, Elisa
    Farolfi, Andrea
    Mei, Riccardo
    Louie, Karly S.
    Groaning, Michael
    Fanti, Stefano
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (06) : 910 - 917
12345